Référentiel des médicaments
Nivolumab
Nivolumab is a medicine in the class oncology. It is used for hodgkin lymphoma.
- Classe médicamenteuse: Oncology
- Indications: hodgkin lymphoma
Dernière mise à jour
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Oncology
- Code ATC
- L01FF01
- Formes courantes
- injection
- Dosages courants
- 10 mg/ml, 40 mg/4 ml, 100 mg/10 ml
- Interactions connues
- 13 (Majeure: 1 · Modérée: 7 · Mineure: 5)
- Noms commerciaux
- 7
- Pays et marchés
- 5
Indications
Mécanisme d'action
Monoclonal antibody to programmed cell death-1 protein (PD-1); blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2
Posologie adulte habituelle (résumé de la notice)
Adjuvant Treatment of Melanoma: 240 mg IV q2Weeks or 480 mg IV q4Weeks
Grossesse et allaitement
- Grossesse
- Unsafe Can cause fetal harm: blocking PD-1 can break immune tolerance of the fetus; in monkeys it increased abortion and premature infant death. It crosses the placenta, mostly in the 2nd and 3rd trimesters. Check pregnancy status; use effective contraception during and for 5 months after.
- Allaitement
- Unsafe In one mother, milk levels were unexpectedly high and rose with repeated doses (an IgG4 antibody), though infant absorption is probably low. LactMed: avoid while breastfeeding. US label: do not breastfeed during treatment and for 5 months after the last dose.
Effets indésirables signalés
- Rash
- Pruritus
- Cough
- Increased AST
- Hyponatremia
- Increased alkaline phosphatase
Précautions particulières
- In combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to drug alone
- Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including immune-mediated pneumonitis
- May cause immune-mediated rash, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (13)
- Nivolumab + Thalidomide Major
- Dexamethasone + Nivolumab Moderate
- Dexamethasone-tobramycin + Nivolumab Moderate
- Efgartigimod / hyaluronidase sc + Nivolumab Moderate
- Efgartigimod alfa + Nivolumab Moderate
- Nivolumab + Ponesimod Moderate
- Nivolumab + Rozanolixizumab Moderate
- Nivolumab + Siponimod Moderate
- Amoxicillin-clavulanic acid + Nivolumab Minor
- Cefalexin + Nivolumab Minor
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Nivolumab : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 7 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Nivolumab used for?
Nivolumab is a medicine in the class oncology. It is used for Hodgkin lymphoma, Lung cancer, Melanoma, Mesothelioma, Renal cell carcinoma.
What side effects have been reported with Nivolumab?
Rash, Pruritus, Cough, Increased AST, Hyponatremia, Increased alkaline phosphatase.
Can Nivolumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: blocking PD-1 can break immune tolerance of the fetus; in monkeys it increased abortion and premature infant death. It crosses the placenta, mostly in the 2nd and 3rd trimesters. Check pregnancy status; use effective contraception during and for 5 months after. Breastfeeding: Unsafe. In one mother, milk levels were unexpectedly high and rose with repeated doses (an IgG4 antibody), though infant absorption is probably low. LactMed: avoid while breastfeeding. US label: do not breastfeed during treatment and for 5 months after the last dose.
What does Nivolumab interact with?
MediHelp lists 13 known interactions for Nivolumab. Major: 1 · Moderate: 7 · Minor: 5. The most serious include Thalidomide, Dexamethasone, Dexamethasone-tobramycin.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
